


**Workshop objective**

- Provide guidance on the potential for joint collection of resource utilisation (RU) and patient-reported outcomes (PROs) data and on methodological issues associated with the use of both measures from existing or collected data.

2



**Workshop context**

- As healthcare payers face greater budgetary constraints, the burden of evidence for new medicines is increasing.
- RU and PROs continue to be used as evidence; however, the timing of their collection is fragmented.
- Data are collected across settings (typically primary and secondary care) and as either part of routine (real-world data) or experimental (e.g., clinical trial) care.
- In addition, the timing of collecting these data varies. During the early phases of drug development, there is a greater focus on obtaining PROs, with RU data becoming more important after proof of concept is established.
- Bridging this apparent gap and collecting and analysing RU and PRO data throughout the process, will contribute to better evidence.

3

